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Aberrant signaling transduction induced by mutant KRAS proteins occurs in 20∼30%
of non-small cell lung cancer (NSCLC), however, a direct and effective pharmacological
inhibitor targeting KRAS has not yet reached the clinic to date. Honokiol, a small
molecular polyphenol natural biophenolic compound derived from the bark of magnolia
trees, exerts anticancer activity, however, its mechanism remains unknown. In this study,
we sought to investigate the in vitro effects of honokiol on NSCLC cell lines harboring
KRAS mutations. Honokiol was shown to induce G1 arrest and apoptosis to inhibit
the growth of KRAS mutant lung cancer cells, which was weakened by an autophagy
inhibitor 3-methyladenine (3-MA), suggesting a pro-apoptotic role of honokiol-induced
autophagy that was dependent on AMPK-mTOR signaling pathway. In addition, we also
discovered that Sirt3 was significantly up-regulated in honokiol treated KRAS mutant
lung cancer cells, leading to destabilization of its target gene Hif-1α, which indicated that
the anticancer property of honokiol maybe regulated via a novel mechanism associated
with the Sirt3/Hif-1α. Taken together, these results broaden our understanding of the
mechanisms on honokiol effects in lung cancer, and reinforce the possibility of its
potential anticancer benefit as a popular Chinese herbal medicine (CHM).
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INTRODUCTION
Lung cancer is the most prevalent type of cancer as well as the leading cause of cancer-related
mortality worldwide. It is estimated that approximately 1.8 million new lung cancer cases and1.6
million deaths occur every year (Herbst et al., 2008; Chen et al., 2016). Non-small cell lung cancer
(NSCLC) accounts for 85% of all lung cancer cases (Chen Z. et al., 2014). Despite advances
in early detection and standard therapies, treatment of NSCLC remains elusive (Herbst et al.,
2008). The treatment and prevention of lung cancer are major un-met needs that can probably
be improved by a better understanding of the molecular mechanism of the driver genes. To date, a
number of driver genes have been identified, including KRAS (v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog), epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor
tyrosine kinase (ALK), proto-oncogene tyrosine kinase c-ROS1(ROS1) (Seo et al., 2012; Cancer
Genome Atlas Research Network, 2014). Among those genes, mutation of KRAS was found in
25–30% of NSCLC (Pylayeva-Gupta et al., 2011). Recent successful targeted therapies, including
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the EGFR inhibitor gefitinib/erlotinib for patients with EGFR
mutation (Lynch et al., 2004; Tsao et al., 2005), and ALK inhibitor
crizotinib for patients with ALK rearrangements (Solomon et al.,
2014).
Mutated KRAS proteins have been widely identified as
potential anticancer targets, which stimulated an extensive search
for small-molecule inhibitors (Cox and Der, 2010). Recently,
a number of small molecules and vaccine strategies targeting
KRAS have been reported (Ostrem and Shokat, 2016). Despite
more than 30 years of considerable effort by researchers, effective
pharmacological inhibitor of targeting KRAS signaling has not
yet been identified to date, due to the lack of well-defined
drug-binding pockets on the surface of KRAS protein (Ostrem
and Shokat, 2016). Compared to KRAS-GTP interaction, the
relatively poor binding affinity of these compounds prompted
a widely held perception that oncogenic KRAS was an
“undruggable” cancer target (Cox et al., 2014).
Traditional Chinese Medicine (TCM) has been widely used
for several thousand years and is the most prolific source of
leading compounds for drug development. It contains various
natural compounds with biological activity, which are claimed
to have therapeutic efficacy with minimal side effects (Liu
et al., 2015). In recent years, TCM-based herbal medicines
have gained increasing acceptance and aroused a great deal
of interest worldwide in cancer therapy (Hsiao and Liu,
2010). Honokiol [(3’,5-di-(2-propenyl)-1,1’-biphenyl-2,2’-diol] is
a natural biphenolic compound derived from an extract of
seed cones and the bark of magnolia trees with anti-oxidative,
anti-inflammatory and anti-tumor properties (Fried and Arbiser,
2009). Several mechanisms of honokiol have suggested that it
maybe be a promising anticancer agent (Averett et al., 2014), such
as the inhibition of STAT3 phosphorylation and the metastases
in lung cancer cells (Pan et al., 2017), as well as the suppression
of the development and progression of lung tumorigenesis by
deregulating EGFR and its downstream effectors (Song et al.,
2016). Honokiol also activated AMP-activated protein kinase in
breast cancer cells via an LKB1-dependent pathway and inhibited
breast carcinogenesis (Nagalingam et al., 2012). It reported that
honokiol suppressed RAS activation by blocking RAS-dependent
phospholipase D (PLD) activity, but the underlying molecular
mechanisms are still unclear (Garcia et al., 2008; Fried and
Arbiser, 2009). In our study, we sought to assess the in vitro effects
of honokiol on NSCLC cell lines harboring KRAS mutations and
investigate its treatment mechanism of action.
RESULTS
Honokiol Inhibits Cell Proliferation and
Colony Formation in KRAS Mutated Cell
Lines
To evaluate the therapeutic potential of honokiol, three human
lung cancer cell lines H460, A549, and H358 cells were cultured
with an increasing concentration of honokiol for 72 h, and then
cell viability was determined by MTT assay. Honokiol inhibited
the growth of H460, A549 and H358 cells in a dose-dependent
manner (Figure 1B), with 50% inhibition concentration (IC50)
at 72 h of 30.42 ± 8.47, 50.58 ± 4.93, and 59.38 ± 6.75 µM,
respectively, but it showed low toxicity to two normal lung
cells (CCD19-Lu and BEAS-2B) (Figure 1A). Subsequently,
we examined the effect of honokiol on cell colony formation,
in accordance with the cell cytotoxicity, honokiol significantly
inhibited the colony formation capacity in a dose-dependent
fashion in KRAS mutated cell lines (Figure 1B).
Honokiol Induces Apoptosis in KRAS
Mutated Cell Lines
To investigate whether the induction of apoptosis also
contributed to honokiol-mediated growth inhibition of KRAS
mutated cells, we used Annexin V-FITC/PI flow cytometry to
analyze the population of apoptotic cells. Results showed that
honokiol-induced apoptosis in the three KRAS mutant cell
lines in a concentration dependent manner (Figure 2A). To
further demonstrate the mechanism by which honokiol induced
apoptosis in these KRAS mutant cell lines, western blotting
assay was performed to evaluate the expression of several
well-characterized apoptotic proteins. As shown in Figure 2B,
honokiol increased the expression of pro-apoptotic protein Bax,
while decreased the expression of anti-apoptotic protein Bcl-2 in
these KRAS mutation cell lines. In addition, PARP cleavage in
honokiol treated cells, further confirmed that honokiol induced
apoptosis in KRAS mutated cells.
Honokiol Suppresses Growth and
Survival Signaling Pathways in KRAS
Mutated Cell Lines
Because growth factor-mediated activation of KRAS is known
to activate the RAF/MEK/ERK and RAF/PI3K/AKT pathway
(Castellano et al., 2013; Samatar and Poulikakos, 2014), we next
examined the effect of honokiol on RAS mediated signaling
transduction in KRAS mutated cells, such as the phosphorylation
status of c-RAF, AKT, and ERK. The results showed that
treatment with honokiol led to a reduction in c-RAF, ERK,
and AKT phosphorylation in three KRAS mutated lung cancer
cell lines (Figure 3). Our data indicated that honokiol inhibited
KRAS mutated cell line growth and survival via regulating KRAS
downstream signaling pathways.
Honokiol Causes Cell Cycle Arrest at G1
Phase in KRAS Mutated Cell Lines
We next evaluated the cell cycle profile of KRAS mutant
cells treated with honokiol. Cells (H460, A549, and H358)
were treated with or without 60 µM honokiol for 24 h
and cell cycle analysis was performed using flow cytometry.
Results showed that treatment with honokiol led to cell
cycle arrest at the G0/G1 phase in KRAS mutated cell
lines (Figure 4A). Furthermore, we determined the effect
of honokiol on cycle-related protein levels of G0/G1 phase
by immunoblotting to gain insights into the mechanism of
honokiol-induced cell cycle arrest in KRAS mutated cell lines.
As shown in Figure 4B, cyclin-dependent kinase inhibitors
p21 and p27 exhibited a promotion in the honokiol-treated
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FIGURE 1 | Effect of honokiol on cell viability and colony formation in KRAS mutant cell lines. (A) Cell viability of KRAS mutant cells and lung normal cells
cultured in the presence of various concentrations of honokiol (0–80 µM) for 72 h, as analyzed by MTT assay, results were expressed as mean ± SE. (B) Colony
formation of KRAS mutant cells was monitored after honokiol (0–60 µM) treatment for 10–14 days, and representative photomicrographs of crystal violet stained
colonies were depicted.
three KRAS mutated cell lines with a marked reduction of
cyclin D1. These results suggested that G1 arrest induced
by honokiol might be attributed to the effect on p21, p27
as well as cyclin D1 and resulted in the inhibition of cell
proliferation.
Honokiol Induces Autophagy via
mTOR-AMPK Dependent Pathway in
KRAS Mutant Lung Cancer Cells
Stiudies reported that honokiol can trigger autophagy (Cheng
et al., 2016; Yeh et al., 2016). In order to determine whether
honokiol could induce autophagy in KRAS mutated cell lines,
we assessed one of the key hallmarks of autophagy: the
conversion of soluble LC3-I to lipid bound LC3-II (Tanida
et al., 2004). As illustrated in Figure 5A, treatment with
honokiol distinctly increased the conversion of LC3-I to LC3-II
of KRAS mutated cells in a concentration-dependent manner,
and this accumulation of LC3-II induced by honokiol was
relieved in the presence of autophagy inhibitor 3-methyladenine
(3-MA), a class III PI3K inhibitor (Figure 5B). AMPK is a
sensor of cellular energy status and it is activated under high
intracellular AMP conditions, thereby induces autophagy via
the AMPK-mTOR dependent pathway (Mihaylova and Shaw,
2011). To investigate whether the effects of honokiol on KRAS
mutated cells relied on this signaling pathway, we examined
the activity of honokiol on the representative signaling cascades.
The results showed that treatment of cells with honokiol
suppressed mTOR phosphorylation, leading to inhibition of
P70S6K kinase activity, which signals cell survival and growth in
transduction pathway (Asnaghi et al., 2004), with concomitant
up-regulation of phospho-AMPK (Figure 5C). Taken together,
our results suggested that honokiol induced autophagy in KRAS
mutated cells was mediated through the AMPK-mTOR signaling
pathway.
Blockade of Autophagy Reduces
Apoptosis in the Honokiol-treated KRAS
Mutant Cells
Although many anti-cancer agents can activate autophagy in
different types of cancers, it remains controversial whether
autophagy promotes cell death or acts as a pro-survival
mechanism (Hippert et al., 2006). To test whether autophagy
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FIGURE 2 | Flow cytometry analysis of honokiol induced apoptosis in KRAS mutant cell lines. (A) KRAS mutant cells (H460, A549, and H358) were treated
with honokiol (10, 20, 40, and 60 µM) for 48 h. Cell apoptosis was analyzed using flow cytometer, triplicate data were plotted as bar chart diagram. (B) Cleaved
PARP, Bax and Bcl2 protein expression was evaluated by immunoblotting of KRAS mutant cells lysates after 48 h of honokiol (10, 20, 40, and 60 µM) treatment.
∗∗P < 0.01 and ∗∗∗P < 0.001 for comparison between control group and honokiol-treated group.
is required for honokiol-mediated growth inhibition in KRAS
mutated cells, we evaluated the impact of autophagy on
honokiol-mediated cytotoxicity by inhibiting autophagy with
3-MA. As shown in Figure 6, compared with use of honokiol
alone, co-treatment with autophagy inhibitor 3-MA led to the
decreased apoptosis in KRAS mutant cells, suggesting that
the honokiol-induced autophagy contributed to its antitumor
activity.
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FIGURE 3 | The effect of honokiol on KRAS signaling in KRAS mutant cell lines. KRAS mutant cells (H460, A549, and H358) were treated with 60 µM
honokiol for 48 h and the levels of p-c-RAF, c-RAF, p-ERK, ERK, p-AKT, and AKT were monitored by western blotting.
FIGURE 4 | Effect of honokiol on cell cycle progression KRAS mutant cell lines. (A) Cell cycle distribution analysis by flow cytometry. H460, A549, and H358
cells were incubated with indicated 60 µM honokiol for 24 h. The cells were collected, stained with PI and analyzed by flow cytometer. Bar diagram showing the
distribution of cells in different phases of the cell cycle. (B) Western blot analysis of cycle-associated proteins. KRAS mutant cells (H460, A549, and H358) were
treated with 60 µM honokiol 24 h. p21, p27, and cyclin D1 protein expression was measured by western blot. ∗∗P < 0.01 and ∗∗∗P < 0.001 for comparison
between control group and honokiol-treated group.
Sirt3 Protein Expression is Decreased in
KRAS Mutated Cell Lines While
Treatment of Honokiol Increases Sirt3
Levels
Previous results have indicated that Sirt3 acts as a tumor
suppressor against lung adenocarcinoma tumor tumorigenesis
by maintaining mitochondrial integrity and efficient oxidative
metabolism (Xiao et al., 2013; Chen Y. et al., 2014). Our
data further confirmed Sirt3 mRNA levels were significantly
downregulated in KRAS mutated cell lines compared with
normal lung epithelial cells (Figure 7A). Similarly, a marked
downregulation of Sirt3 protein levels was observed in KRAS
mutated cell lines (Figure 7C). Recently, researchers discovered
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FIGURE 5 | Honokiol induced autophagy though AMPK-mTOR dependent pathway in KRAS mutant lung cancer cells. (A) KRAS mutant cells (H460,
A549, and H358) were treated with honokiol (20, 40, and 60 µM) for 24 h, the conversion of LC3-Ito LC3-II was determined by Western blot. (B) Cells were treated
with 60 µM honokiol, 5 mM 3-MA or combination of both, the conversion of LC3-I to LC3-II was determined by Western blot. (C) Cells were treated with 60 µM
honokiol for 24 h, p-mTOR, mTOR, p-AMPK, AMPK, p-P70S6K, and P70S6K protein expression was evaluated by immunoblotting.
that honokiol might be a pharmacological activator of Sirt3 (Pillai
et al., 2015), so we wondered whether honokiol can regulate Sirt3
levels in KRAS mutated cell lines. Sirt3 could mediate metabolic
reprogramming in human breast cancer cells by destabilizing
Hif-1α (Bell et al., 2011), The results showed that treatment of
cells with honokiol increased both mRNA and protein levels
of Sirt3 (Figure 7B), accompanied by a reduction of Hif-1a
expression (Figure 7D), which can be destabilized by Sirt3
mediated metabolic reprogramming in human breast cancer cells
(Bell et al., 2011). Collectively, these observations indicated that
the anti-cancer effect of honokiol is mediated by activating Sirt3
expression.
DISCUSSION
Honokiol has generated an extensive interest in cancer research
due to its multi-functional effects such as inducing anti-tumor
growth, anti-migration, anti-angiogenesis and anti-multiple drug
resistance (Kumar et al., 2013; Pan et al., 2016). As a novel agent
for cancer therapy, honokiol, targets multiple signaling pathways,
including nuclear factor kappa B (NF-κB) (Ahn et al., 2006),
signal transducers and activator of transcription 3 (STAT3),
epidermal growth factor receptor (EGFR) (Leeman-Neill et al.,
2010; Song et al., 2016) and mammalian target of rapamycin
(m-TOR) (Lin et al., 2016), all of which have great relevance
during cancer initiation and progression. In this study, we
reported for the first time honokiol induced apoptosis, G1 arrest,
as well as autophagy mediated cell death in KRAS mutant lung
cancer cells, and honokiol blocked KRAS mutant lung cancer
cells growth by activating mitochondrial Sirt3 and suppressing
HIF-1α expression (Figure 8).
Previous studies demonstrated that, honokiol induced
cytotoxicity in various human cancer cell lines (Arora et al., 2011;
Avtanski et al., 2015; Zhang et al., 2015). Here, we demonstrated
the cytotoxic function of honokiol in lung cancer cells harboring
oncogenic KRAS for the first time. We found that honokiol
induced cytotoxicity and inhibited proliferation of KRAS mutant
lung cancer cells, compared to the normal lung cells with lower
cytotoxicity. Cell proliferation needs cell cycle progression,
which is known to be regulated positively by cyclin-CDK (cyclin
dependent kinase) complexes such as cyclinB1 and cyclin D1,
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FIGURE 6 | Blockade of autophagy reduced apoptosis of the honokiol-treated KRAS mutant cells. KRAS mutant cells (H460, A549, and H358) were
treated with 60 µM honokiol, 5 mM 3-MA, or a combination of both, and cell apoptosis was measured by Annexin V/PI double staining with flow cytometry.
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.
but negatively by CDK inhibitors such as p21 and p27 (Lacy
et al., 2004; Orlando et al., 2015). Cell proliferation needs cell
cycle progression. We observed that honokiol caused G1-phase
arrest of cell cycle progression, which might be attributed to
the reduction of cyclin D1 and enhanced expression of p21,
as well as p27. Following G1-phase cell cycle arrest, cells may
enter the apoptotic pathway. In the present study, we observed
induction of apoptosis in honokiol-treated KRAS mutant lung
cancer cells, which was supported by an increased amount of
cleaved PARP and pro-apoptotic proteins Bax, with a reduction
of anti-apoptotic Bcl-2 protein.
Autophagy is an evolutionarily self-digesting process in
which cytoplasmic material is sequestered within cytosolic
double-membraned vesicles-autophagosomes, and ends up in the
lysosome (Karsli-Uzunbas et al., 2014). Autophagy has a context-
dependent role in cancer, which is considered as a double-edged
sword in suppression and promotion of tumorigenesis (White
and DiPaola, 2009). Furthermore, recent studies suggested
that autophagy is required for mitochondrial function, lipid
metabolism, growth, and fate of KRASG12D-driven lung tumor
(Guo and White, 2013), as well as autophagy suppresses
progression of KRAS-induced lung tumors to oncocytomas and
maintains lipid homeostasis (Guo et al., 2013). In our study, in
KRAS mutant cells, honokiol caused the conversion of LC3-I
to LC3-II, which provided an indicator of autophagic activity
and could be reversed by autophagy inhibitor 3-MA, displaying
its ability of inducing autophagy. Furthermore, our results
revealed that honokiol-induced autophagy is dependent on the
AMPK-mTOR signaling pathway, which has been addressed in
autophagocytosis (Lin et al., 2016; Lu et al., 2017). Honokiol-
induced autophagy may perform a pro-death process in KRAS
mutant lung cancer cells, but not pro-survival response, as
autophagy inhibitor 3-MA was application reduced honokiol-
mediated cytotoxicity.
Sirt3, a member of the mammalian sirtin family protein that
is localized to mitochondria, is a NAD+-dependent deacetylase
and plays an important role in the control of metabolic activity
(Haigis et al., 2012). Recently, studies have shown that Sirt3
acts as a tumor suppressor in lung adenocarcinoma development
and progression and may be a promising therapeutic target for
lung adenocarcinoma (Li et al., 2013; Akamata et al., 2016).
Honokiol is a pharmacological activator of Sirt3 capable of
blocking or even reversing the cardiac hypertrophic response
(Pillai et al., 2015). Consistent with previous reports, we
demonstrated that Sirt3 was significantly downregulated in
KRAS mutant lung cancer cells compared with normal lung
cells, which could be enhanced by honokiol treatment. In
addition, honokiol also weakened Hif-1a expression, a Sirt3
downstream effector (Bell et al., 2011). It was reported that
Sirt3 is related to autophagy, indicating the attenuation of
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FIGURE 7 | Sirt3 protein expression was decreased in KRAS mutant cell lines and treatment honokiol increased Sirt3 levels. (A) mRNA level of Sirt3 in
KRAS mutant lung cancer cells and normal lung cell was measured by RT-PCR analysis. ∗∗∗P < 0.001, as compared to normal cells. (B) Cells lysate of different cell
lines was subjected to immunoblotting using Sirt3 antibody. (C) KRAS mutant cells (H460, A549, and H358) were treated with 60 µM honokiol for 24 h and mRNA
level of sirt3 was measured by RT-PCR analysis. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001, as compared to the untreated group. (D) KRAS mutant cells (H460, A549,
and H358) were treated with 60 µM honokiol for 24 h. Cell lysate was analyzed by western-blot with Sirt3 and Hif-1α antibodies.
cardiomyocytes hypertrophy by promoting autophagy (Li et al.,
2016). Additionally, melatonin exerts a hepatoprotective effect
on mitochondrial-derived O•−2 -stimulated autophagic cell death
that is dependent on the SIRT3/SOD2 pathway (Pi et al., 2015).
Therefore, our results suggested honokiol induced autophagy
in KRAS mutant lung cancer cells could be attributed to Sirt3-
Hif-1α pathway.
In summary, the findings here demonstrated the bioactivities
of honokiol. It has a strong potential as an anticancer agent
because of its ability to induce G1 arrest and apoptosis to inhibit
KRAS mutant lung cancer cell growth by disrupting oncogenic
KRAS-mediated RAF/MEK/ERK and RAF/PI3K/AKT signaling
pathway. Importantly, honokiol triggers pro-death autophagy,
which may result from the Sirt3/Hif-1a pathway. Our results thus
provide a foundation for scientific and clinical development of
honokiol against KRAS-driven cancers.
MATERIALS AND METHODS
Cell Lines and Reagents
H460, A549, H358, H2122, BEAS-2B, NIH3T3, CCD19-Lu cells
were obtained from the American Type Culture Collection and
cultured in an environment of 5% CO2 at 37◦C in RPMI-
1640 medium supplemented with 10% fetal bovine serum (FBS),
CCD19-Lu cells were grown in MEM medium supplemented
with 10% FBS, BEAS-2B cells were maintained in BEBM
containing 0.01 mg/ml fibronectin, 0.03 mg/ml bovine collagen
type I and 0.01 mg/ml bovine serum albumin. All cells were added
100 units/ml penicillin, and 100 µg/ml streptomycin. Honokiol
was purchased from Selleck Chemicals. Antibodies to GAPDH,
C-RAF, p-C-RAF, p-AKT (Ser473), p-ERK (Thr202/Thy204),
P21, P27, Cyclin D1, Sirt3, Hif-1α, and ERK were purchased
from cell signaling technology. Anti-AKT, KRAS antibody were
acquired from Santa Cruz Biotechnology.
Cell Viability Assay
Cell viability was assayed using 3-(4.5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide (MTT). Briefly, KRAS mutant cells
(H460, A549, and H358) were seeded in a 96-well plate at a
density of 3 × 103 cells/well for 24 h, respectively, and were
cultured overnight for cell adhesion, then treated with different
concentrations honokiol (0–80 µM) for another 72 h. At the
end of treatment, 10 µl MTT (5 mg/ml) solution was added to
each well and further incubated at 37◦C for 4 h, then 100 µl
of the resolved solution (10% SDS and 0.1 mm HCL) was
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FIGURE 8 | Schematic illustration the mechanism of Sirt3 activation by honokiol.
added to each well to dissolve the MTT formazan crystals.
Absorbance was measured at a wavelength of 570nm with
BioRad microplate reader (FluoDia T70, Photon Technology
International, Lawrenceville, NJ, USA), the cell viability is
calculated as the percentages change of the absorbance of treated
cells divided by the absorbance of untreated cells. The IC50
value for the compound was determined by GraphPad Prim5.0
software.
Colony Formation Assay
Briefly, KRAS mutant cells (H460, A549, and H358) were seeded
in 6-well plates (500 cells/well), after attachment overnight, cells
were exposed to various concentration of honokiol with medium
changes every 3 days until visible colonies formed. The colonies
were washed with cold PBS, then fixed in 4% paraformaldehyde
(PFA) for 15 min, and stained with 0.5% crystal violet (1% PFA,
0.5% crystal violet, and 20% methanol in ddH2O) for 20 min. The
colonies were photographed.
Annexin V and PI Staining Assay
KRAS mutant cells (H460, A549, and H358) were treated with
various concentrations of honokiol (0, 10, 20, 40, and 60 µM)
for 48 h. Cells were washed with PBS and resuspended in 1×
binding buffer (100 µl). One microliter of annexin V (AV)-
fluorescein isothiocyanate solution (2.5 µg/ml) and 1 µl of
dissolved propidium iodide (PI) (50 µg/ml) were added to the
cell suspensions vortexed and incubated at room temperature in
the dark for 15 min. 400 µl of chilled 1× binding buffer was
added and mixed gently prior to the examination of the cell
preparations by flow cytometry (FACSCalibur, BD Biosciences), a
minimum of 10,000 events were collected and analyzed, and data
were analyzed with the Flow J software.
Cell Cycle Analysis
Briefly, KRAS mutant cells (H460, A549, and H358) were seeded
on a 6-well plate at 1 × 105 cells/well for 24 h, respectively,
after treatment with 60 µM honokiol for another 24 h. The
cells collected and washed with PBS, followed by fixation with
70% (v/v) ethanol at –20◦C overnight. Thereafter, cells were
washed and resuspended in 500 µl PBS containing 50 µg/ml
PI and 1 mg/ml RNaseA for 30 min at room temperature in
the dark. In total, 10,000 events were analyzed immediately
in each sample subjected to flow cytometer (FACSCalibur, BD
Biosciences), and the percentages of cells in G1, S and G2/M
phases were calculated.
Immunoblotting
Whole-cell lysates were rinsed with ice-cold PBS and lysed in
RIPA Lysis buffer (150 mM NaCl, 50 mM Tris pH 7.4, 1 mM
EDTA, 0.25% sodium deoxycholate, 1% NP-40,) containing
protease (Roche) and phosphatase (Roche) inhibitors. Lysates
were centrifuged at 14,100 × g for 10 min at 4◦C. Thirty
microgram of total protein from each sample was separated
on a 10-12% polyacrylamide gel, and then transferred to a
nitrocellulose membrane (Millipore). Immunoblots were blocked
with 5% skim milk in TBS/Tween 20 (0.05%, v/v) for 1 h at
RT, followed by overnight incubation at 4◦C with primary anti-
bodies. After washing three times with TBST, the membranes
were incubated with secondary rabbit or mouse fluorescent
antibodies for 1 h in the dark, then the signal intensity of
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the membranes was scanned on a LI-COR Odessy imaging
system (Belfast). All primary antibodies were diluted in 1:1000,
while their recommended secondary antibodies were diluted in
1:10000.
RNA Isolation and Quantitative Real-time
PCR
Total RNA was extracted from the cultured cells using
Trizol reagent (Invitrogen) according to the manufacturer’s
instructions. Total RNA (1 µg) was converted into cDNA
using the PrimeScriptTM RT reagent kit with gDNA Eraser
(Takara) according to the manufacturer’s instructions. RT-PCR
was performed using SYBR R© Premix Ex TaqTM II (Takara) in the
ABI PRISM R© 7300 real-time PCR system (Applied Biosystems).
The 2−11Ct method was used to calculate relative expression
level.
Statistical Analysis
GraphPad Prism 5.0 software was used to analysis data statistic.
The results were presented as the mean ± standard deviation
(SD). Statistical analysis was carried out using Student’s t-test
or one-way analysis of variance. P-values < 0.05 were regarded
statistically significant.
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